CERo Therapeutics Holdings, Inc.

CEROOTCHealthcare● Active

$0.01

$-0.00(-13.64%)

Market Cap$12596

P/E Ratio—

52W High$26.99

52W Low$0.01

Avg Volume605K

Open$0.01

Beta0.12

Insider Trades Ownership Employees

CERo Therapeutics Holdings, Inc. (CERO) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · CERO · as of Jun 9, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

CERo Therapeutics Holdings, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

CERO insider buying and selling by quarter

CERO insider selling · CERO insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

25.6M12.8M0

2024 Q1

2024 Q2

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2026 Q1

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Recent insider transactions

CERO executive sell shares · CERO board member insider trading · CERO insider trading SEC filing

Showing 18 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Mar 31, 2025	ATWOOD BRIAN G Director	Option	294,460	$0.00	$29	490,534	Form 4
Dec 11, 2024	YK Bioventures Opportunities GP I, LLC 10 percent owner	Sale	1,343,801	$0.08	$108K	17,618,618	Form 4
Dec 12, 2024	YK Bioventures Opportunities GP I, LLC 10 percent owner	Sale	1,614,541	$0.07	$113K	16,004,077	Form 4
Dec 13, 2024	YK Bioventures Opportunities GP I, LLC 10 percent owner	Sale	2,998,908	$0.06	$180K	13,005,169	Form 4
Dec 6, 2024	YK Bioventures Opportunities GP I, LLC 10 percent owner	Sale	1,236,874	$0.12	$148K	21,383,909	Form 4
Dec 9, 2024	YK Bioventures Opportunities GP I, LLC 10 percent owner	Sale	850,543	$0.11	$94K	20,533,366	Form 4
Dec 10, 2024	YK Bioventures Opportunities GP I, LLC 10 percent owner	Sale	1,570,947	$0.09	$141K	18,962,419	Form 4
Oct 10, 2024	YK Bioventures Opportunities GP I, LLC 10 percent owner	Sale	3,250,000	$0.10	$325K	22,620,783	Form 4
Sep 25, 2024	LAPORTE KATHLEEN Director	Option	965,997	$1000.00	$966.00M⚡	965,997	Form 4
Sep 25, 2024	Ehrlich Christopher B Interim Chairman and CEO · Director	Option	5,312,983	$1000.00	$5.31B⚡	5,791,808	Form 4
Sep 25, 2024	ATWOOD BRIAN G Director	Option	19,358,578	$1000.00	$19.36B⚡	19,607,313	Form 4
Feb 14, 2024	PHOENIX BIOTECH SPONSOR, LLC 10 percent owner	Other	1,125,000	—	—	4,171,246	Form 4
Feb 14, 2024	PHOENIX BIOTECH SPONSOR, LLC 10 percent owner	Other	4,171,246	—	—	1,000,000	Form 4
Feb 14, 2024	LAPORTE KATHLEEN Director	Other	5,828	—	—	5,828	Form 4
Feb 14, 2024	Ehrlich Christopher B Director	Other	1,125,000	—	—	4,171,246	Form 4
Feb 14, 2024	Ehrlich Christopher B Director	Other	4,171,246	—	—	1,000,000	Form 4
Feb 14, 2024	Ehrlich Christopher B Director	Other	478,825	—	—	478,825	Form 4
Feb 14, 2024	Ehrlich Christopher B Director	Other	3,600	—	—	3,600	Form 4

ATWOOD BRIAN G

Director

Option

Date

Mar 31

294,460

Price

$0.00

Value

$29

View Form 4 on SEC.gov

YK Bioventures Opportunities GP I, LLC

10 percent owner

Sale

Date

Dec 11

1,343,801

Price

$0.08

Value

$108K

View Form 4 on SEC.gov

YK Bioventures Opportunities GP I, LLC

10 percent owner

Sale

Date

Dec 12

1,614,541

Price

$0.07

Value

$113K

View Form 4 on SEC.gov

YK Bioventures Opportunities GP I, LLC

10 percent owner

Sale

Date

Dec 13

2,998,908

Price

$0.06

Value

$180K

View Form 4 on SEC.gov

YK Bioventures Opportunities GP I, LLC

10 percent owner

Sale

Date

Dec 6

1,236,874

Price

$0.12

Value

$148K

View Form 4 on SEC.gov

YK Bioventures Opportunities GP I, LLC

10 percent owner

Sale

Date

Dec 9

850,543

Price

$0.11

Value

$94K

View Form 4 on SEC.gov

YK Bioventures Opportunities GP I, LLC

10 percent owner

Sale

Date

Dec 10

1,570,947

Price

$0.09

Value

$141K

View Form 4 on SEC.gov

YK Bioventures Opportunities GP I, LLC

10 percent owner

Sale

Date

Oct 10

3,250,000

Price

$0.10

Value

$325K

View Form 4 on SEC.gov

LAPORTE KATHLEEN

Director

Option

Date

Sep 25

965,997

Price

$1000.00

Value

$966.00M ⚡

View Form 4 on SEC.gov

Ehrlich Christopher B

Interim Chairman and CEO · Director

Option

Date

Sep 25

5,312,983

Price

$1000.00

Value

$5.31B ⚡

View Form 4 on SEC.gov

ATWOOD BRIAN G

Director

Option

Date

Sep 25

19,358,578

Price

$1000.00

Value

$19.36B ⚡

View Form 4 on SEC.gov

PHOENIX BIOTECH SPONSOR, LLC

10 percent owner

Other

Date

Feb 14

1,125,000

Price

—

Value

—

View Form 4 on SEC.gov

PHOENIX BIOTECH SPONSOR, LLC

10 percent owner

Other

Date

Feb 14

4,171,246

Price

—

Value

—

View Form 4 on SEC.gov

LAPORTE KATHLEEN

Director

Other

Date

Feb 14

5,828

Price

—

Value

—

View Form 4 on SEC.gov

Ehrlich Christopher B

Director

Other

Date

Feb 14

1,125,000

Price

—

Value

—

View Form 4 on SEC.gov

Ehrlich Christopher B

Director

Other

Date

Feb 14

4,171,246

Price

—

Value

—

View Form 4 on SEC.gov

Ehrlich Christopher B

Director

Other

Date

Feb 14

478,825

Price

—

Value

—

View Form 4 on SEC.gov

Ehrlich Christopher B

Director

Other

Date

Feb 14

3,600

Price

—

Value

—

View Form 4 on SEC.gov

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About CERO insider trading

CERO insider trades

CERo Therapeutics Holdings, Inc. (CERO) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including CERO. Over the past 12 months, 0 insiders have filed transactions with the SEC. CERO insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For CERo Therapeutics Holdings, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

CERO insider trading · 5 questions

The insiders of CERo Therapeutics Holdings, Inc. (CERO) include executives and directors such as CERO, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

CERO board member insider tradingwho are CERO insidersCERO insider rosterCERo Therapeutics Holdings, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026